SAM
ALLO icon

Smartleaf Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Smartleaf Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Hold
137,874
– – 0.01% 680
2026
Q1 		$306K Buy
137,874
+108,947
+377% +$218K 0.01% 649
2025
Q4 		$37.9K Buy
+28,927
New +$38.2K ﹤0.01% 1687
2025
Q2 		– Sell
-2,000
Closed -$3.1K – 2725
2025
Q1 		$3.1K Buy
+2,000
New +$3.77K ﹤0.01% 2358

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Smartleaf Asset Management's ALLO Position: Q2 2026 in Review

Smartleaf Asset Management held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 137,874 shares worth $306K. The position accounts for 0.01% of the portfolio, ranked #680.

Smartleaf Asset Management first reported a position in ALLO in Q1 2025 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Smartleaf Asset Management held 137,874 shares of Allogene Therapeutics worth $306K as of Q2 2026.
  • Smartleaf Asset Management left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up 0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #680 holding.
  • Smartleaf Asset Management first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.